7
Participants
Start Date
June 30, 2010
Primary Completion Date
December 31, 2012
Study Completion Date
April 30, 2013
PCI-24781
Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
Sarah Cannon Research Institute, Nashville
Horizon Oncology Center, Lafayette
Northwestern Univ. Med School, Chicago
Nebraska Methodist Hospital, Omaha
Univ. of Nebraska Medical Center, Omaha
Lead Sponsor
Pharmacyclics LLC.
INDUSTRY